GILD Reports Solid Numerical Data For Quad Combo Pill

Analysts at Cowen & Co maintain their "outperform" rating on Gilead Sciences Inc (NASDAQ: GILD).

Numerical data from the Phase II proof-of-concept studies of Gilead Sciences’ Quad Combo pill and GS9350, GILD’s proprietary PK booster, were solid. The results “provide us with increased confidence in the Quad Combo pill’s successful future development,” the analysts say.

“We continue to like GILD, and expect that through a combination of HIV market growth, share gains, and price increases, GILD will continue to outpace long-term Street estimates, and our own projections for 15% top-line and 19% bottom line 2008-14 growth,” the analysts add.

More Analyst Ratings here